EP1047942A4 - Procedes et compositions d'identification de substances mimetiques de facteurs de croissance, de facteurs de croissance et d'inhibiteurs - Google Patents

Procedes et compositions d'identification de substances mimetiques de facteurs de croissance, de facteurs de croissance et d'inhibiteurs

Info

Publication number
EP1047942A4
EP1047942A4 EP99903279A EP99903279A EP1047942A4 EP 1047942 A4 EP1047942 A4 EP 1047942A4 EP 99903279 A EP99903279 A EP 99903279A EP 99903279 A EP99903279 A EP 99903279A EP 1047942 A4 EP1047942 A4 EP 1047942A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
compositions
identification
methods
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99903279A
Other languages
German (de)
English (en)
Other versions
EP1047942A1 (fr
Inventor
Katherine S Bowdish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Antibody Technologies Inc
Original Assignee
Alexion Antibody Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Antibody Technologies Inc filed Critical Alexion Antibody Technologies Inc
Publication of EP1047942A1 publication Critical patent/EP1047942A1/fr
Publication of EP1047942A4 publication Critical patent/EP1047942A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP99903279A 1998-01-23 1999-01-22 Procedes et compositions d'identification de substances mimetiques de facteurs de croissance, de facteurs de croissance et d'inhibiteurs Withdrawn EP1047942A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7225398P 1998-01-23 1998-01-23
US72253P 1998-01-23
PCT/US1999/001331 WO1999038008A1 (fr) 1998-01-23 1999-01-22 Procedes et compositions d'identification de substances mimetiques de facteurs de croissance, de facteurs de croissance et d'inhibiteurs

Publications (2)

Publication Number Publication Date
EP1047942A1 EP1047942A1 (fr) 2000-11-02
EP1047942A4 true EP1047942A4 (fr) 2002-10-30

Family

ID=22106479

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99903279A Withdrawn EP1047942A4 (fr) 1998-01-23 1999-01-22 Procedes et compositions d'identification de substances mimetiques de facteurs de croissance, de facteurs de croissance et d'inhibiteurs

Country Status (5)

Country Link
EP (1) EP1047942A4 (fr)
JP (2) JP3515072B2 (fr)
AU (1) AU2333999A (fr)
CA (1) CA2316755C (fr)
WO (1) WO1999038008A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001401D0 (en) * 2000-01-22 2000-03-08 Univ Edinburgh Methods for amplifying genetic material and use thereof
AU8617301A (en) 2000-08-01 2002-02-13 Yissum Res Dev Co Directed differentiation of embryonic cells
WO2002033073A1 (fr) * 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agoniste degrade
US7732149B2 (en) 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
JP2004016021A (ja) 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2667678A1 (fr) 2006-10-25 2008-07-24 Amgen Inc. Agents therapeutiques a base de peptides toxiques
EP2162540A2 (fr) 2007-05-22 2010-03-17 Amgen Inc. Compositions et procédés pour produire des protéines de fusion bioactives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027062A1 (fr) * 1994-04-04 1995-10-12 Genentech, Inc. Anticorps agonistes diriges contre le recepteur flk2/flt3 et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3434393A (en) * 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
WO1993018136A1 (fr) * 1992-03-05 1993-09-16 Cytomed, Inc. Procede de maintien de cellules souche hematopoietiques
IL106255A0 (en) * 1993-04-23 1993-11-15 Baxter Int Method for isolating human blood cells
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5753516A (en) * 1995-02-03 1998-05-19 Heagy; Wyrta E. Screening method for ligands of the EBI-1 receptor
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027062A1 (fr) * 1994-04-04 1995-10-12 Genentech, Inc. Anticorps agonistes diriges contre le recepteur flk2/flt3 et leurs utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG Y-W ET AL: "A MONOCLONAL ANTI-HUMAN IL-6 RECEPTOR ANTIBODY INHIBITS THE PROLIFERATION OF HUMAN MYELOMA CELLS", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 5, no. 12, October 1993 (1993-10-01), pages 621 - 630, XP001069958, ISSN: 0272-457X *
KRUIF DE J ET AL: "SELECTION AND APPLICATION OF HUMAN SINGLE CHAIN FV ANTIBODY FRAGMENTS FROM A SEMI-SYNTHETIC PHAGE ANTOBODY DISPLEY LIBRARY WITHDESIGNED CDR3 REGIONS", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 248, no. 1, 21 April 1995 (1995-04-21), pages 97 - 105, XP000646544, ISSN: 0022-2836 *
NISHIDA Y ET AL: "CLONING AND EXPRESSION OF A SINGLE-CHAIN FV FRAGMENT SPECIFIC FOR THE HUMAN INTERLEUKIN 18 RECEPTOR", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 17, no. 6, December 1998 (1998-12-01), pages 577 - 580, XP000973543, ISSN: 0272-457X *
See also references of WO9938008A1 *

Also Published As

Publication number Publication date
WO1999038008A1 (fr) 1999-07-29
CA2316755A1 (fr) 1999-07-29
EP1047942A1 (fr) 2000-11-02
JP2003517566A (ja) 2003-05-27
AU2333999A (en) 1999-08-09
JP3515072B2 (ja) 2004-04-05
CA2316755C (fr) 2006-04-04
JP2004123695A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
IL140686A0 (en) Compositions and methods for inhibiting fungal growth
EP1115389A4 (fr) Fructosamine-oxydase: antagonistes et inhibiteurs
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
HUP0101804A3 (en) Adjuvant composition and methods for its use
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
HUP0101625A3 (en) New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
HUP0203746A3 (en) Novel composition and method for stabilizing the same
IL138387A0 (en) Enzyme inhibitors
HK1040076A1 (zh) 作為整聯蛋白抑制劑的喹嗪酮
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
IL138906A0 (en) Quinolones used as mrs inhibitors and bactericides
EP1088333A4 (fr) Compositions et procedes inhibant la resorption osseuse
GB9817235D0 (en) Compound,composition and use
AU4577999A (en) Methods and compositions for inhibiting corrosion
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
GB9817236D0 (en) Compound,composition and use
MXPA01006686A (es) Composiciones fungicidas quirales de imidazol y metodos para su utilizacion.
EP1047942A4 (fr) Procedes et compositions d'identification de substances mimetiques de facteurs de croissance, de facteurs de croissance et d'inhibiteurs
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
GB9903447D0 (en) Compound, composition and use
GB0100361D0 (en) Compound, composition and use
GB9816358D0 (en) Enzyme inhibitors
EP1089750A4 (fr) Compositions et procedes permettant d'inhiber la resorption d'un os
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions
MXPA00006072A (es) Metodos y composiciones para inhibir el crecimiento de celulas tumorales.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000706;LT PAYMENT 20000706;LV PAYMENT 20000706;MK PAYMENT 20000706;RO PAYMENT 20000706;SI PAYMENT 20000706

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALEXION ANTIBODY TECHNOLOGIES INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20020918

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040420

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060831